Daniel Hamstra, MD, PhD, on Prostate Cancer: Decreasing Rectal Toxicity
2016 ASTRO Annual MeetingDaniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)
Related Videos
Joanne B. Weidhaas, MD, PhD, on Head and Neck Cancer: Results of the NRG Oncology/RTOG 0522 Study
Joanne B. Weidhaas, MD, PhD, of the University of California, Los Angeles Radiation Oncology, discusses the KRAS variant as a biomarker of cetuximab response and altered immu...
Howard M. Sandler, MD, on RTOG’s Past and NRG’s Future
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed fo...
Maria Werner-Wasik, MD, on Issues in Lung Toxicity
Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation ...
Paul L. Nguyen, MD, on Prostate Cancer: High-Risk Disease, Brachytherapy, And Hormones
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability a...
Anders Widmark, MD, PhD, on Intermediate-Risk Prostate Cancer: Results From the HYPO-RT-PC Trial
Anders Widmark, MD, PhD, of the Umea University Hospital Oncology, discusses the early toxicity results from the phase III Scandinavian study on extreme hypofractionation vs conventio...
